Prof James Catto from the University of Sheffield described the findings as a "major breakthrough" in treating bladder cancer ...
The most important take-home information from the INTERLACE trial is that in some people with cervical cancer that are ...
R-5780, an oral immuno-oncology drug designed to activate gut-regulated immune pathways, will now be evaluated in a phase 1 ...
The Independent on MSN2d
‘Game changer’ immunotherapy drug could lead to increased survival rates for bladder cancer patientsThe study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or ...
Colorectal cancer (CRC) is a type of cancer that begins in the colon (large intestine) or rectum, which are parts of the ...
Cancer is a disease of the genome, according to Dr. Elli Papaemmanuil, computational oncologist at MSK. By looking at the ...
Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical ...
News Medical on MSN1d
New drug cocktail enhances CAR-T cells for cancer treatmentPreclinical research findings from the University of North Carolina Lineberger Comprehensive Cancer Center identified a cocktail of three different drugs that can be used to generate more robust ...
Live Science on MSN2d
New treatment for most aggressive brain cancer may help patients live longerA new therapy for the most aggressive type of brain cancer can extend patients' survival while cutting the length of ...
Merck CEO Rob Davis told CNBC’s Jim Cramer that there’s more to the pharmaceutical giant than its lucrative cancer drug, ...
Overall survival at two years was 82.2% in the durvalumab group and 75.2% in the comparator group. Durvalumab (brand name ...
Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback